Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials

We evaluated the changes in heart rate on the treatment with SGLT2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus (T2DM). It is suggested that luseogliflozin can effectively decrease in heart rate in patients with higher baseline.[Image: see text]

Detalles Bibliográficos
Autores principales: Sano, Motoaki, Chen, Shi, Imazeki, Hisae, Ochiai, Hidekazu, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934252/
https://www.ncbi.nlm.nih.gov/pubmed/29750107
http://dx.doi.org/10.1111/jdi.12726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934252/
https://www.ncbi.nlm.nih.gov/pubmed/29750107
http://dx.doi.org/10.1111/jdi.12726

Ejemplares similares